Cefuroxime oral

CLINICAL USE


Antibacterial agent

DOSE IN NORMAL RENAL FUNCTION

125–500 mg every 12 hoursGonorrhoea: single dose of 1 g

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :510.5 (as axetil)
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :50
  • %Excreted unchanged in urine &nbsp &nbsp : 85–90

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.13–1.8

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1.2/17

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Dialysed. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp :Dialysed. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAnticoagulants: effects of coumarins may be enhanced

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    –

    Comments

    Take with or after food .134 CEFUroXiME (PArEnTErAL)

    CLINICAL USE


    Antibacterial agent

    DOSE IN NORMAL RENAL FUNCTION

    750 mg – 1.5 g every 6–8 hoursMeningitis: 3 g every 8 hours

    PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :446.4 (as sodium salt)
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :50
  • %Excreted unchanged in urine &nbsp &nbsp : 85–90

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.13–1.8

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1.2/17

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : 750 mg – 1.5 g every 8 hours
  • 10 to 20 &nbsp &nbsp : 750 mg – 1.5 g every 8–12 hours
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 750 mg – 1.5 g every 12–24 hours

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL/min

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL/min
  • HDF/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL/min
  • CAV/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR=10–20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAnticoagulants: effects of coumarins may be enhanced

    ADMINISTRATION

    Reconstition

    IM: 1 mL of water for injection to each 250 mgIV bolus: 2 mL of water for injection to each 250 mg, but 15 mL of water for injection to 1.5 g

    IV infusion

    : 1.5 g in 50 mL of water for injection

    Route

    IM, IV

    Rate of Administration

    IV bolus: over 3–5 minutes

    IV infusion

    : over 30 minutes

    Comments

    Do not mix in syringe with aminoglycoside antibioticsInjection may also be reconstituted with: sodium chloride 0.9%, glucose 5%, glucose saline, Hartmann’s solutionCefuroxime and metronidazole can be mixed (see manufacturer’s guidelines)

    OTHER INFORMATION

    At high doses, take care in patients receiving concurrent treatment with potent diuretics such as furosemide, or aminoglycosides, as combination can adversely affect renal functionEach 750 mg vial ≡ 1.8 mmol sodiumCefuroxime (parenteral).
    Tags:

    • Related News

    sotalol hydrochloride.txt

    tazocin.txt